Finally! If you have ever cared for someone experiencing agitation related to dementia, you know how difficult those moments can be. Agitation treatment in dementia has long been a challenge for caregivers and healthcare providers alike. Agitation is a common and distressing symptom in residents living with Alzheimer’s disease dementia. It is often characterized by excessive motor activity, verbal aggression, or physical aggression. These symptoms can greatly affect quality of life for both residents and caregivers.

On April 30, 2026, the FDA announced the approval of an expanded use for Auvelity to treat agitation associated with Alzheimer’s disease and other dementias. Auvelity contains dextromethorphan hydrobromide and bupropion hydrochloride in an extended-release tablet. This approval is important because it is the first FDA-approved treatment for this condition that is not classified as an antipsychotic medication. FDA Commissioner Marty Makary, M.D., M.P.H., called the approval “a significant advancement” for patients and families dealing with one of the most challenging aspects of Alzheimer’s disease.

As with all medications, there are possible side effects. Reported side effects include dizziness, upset stomach, headache, diarrhea, drowsiness, dry mouth, sexual dysfunction, and uncontrolled sweating. There is also a Black Box warning regarding an increased risk of suicidal thoughts and behaviors in young adults. This new agitation treatment in dementia should become part of your next QAPI, pharmacy, or behaviors management discussion. Communities should evaluate whether this medication may be appropriate for certain residents while carefully considering risks, benefits, monitoring needs, and resident-specific factors.

Even though this medication is not classified as an antipsychotic, obtaining informed consent before initiation would be strongly recommended. Careful monitoring and communication remain essential with any newly approved medication, especially when caring for residents living with dementia.

Stay well and stay informed!